2010 Press releases
Clavis Pharma’s elacytarabine granted FDA Fast Track designation in USA
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that its clinical development programme with elacytarabine for the treatment of patients with acute myeloid leukaemia (AML) ...
Clavis Pharma’s NOK 154 million Private Placement approved at Extraordinary General Meeting
Clavis Pharma ASA (OSE: CLAVIS) announces that all items proposed to shareholders at its extraordinary general meeting held today in Oslo were resolved according the Board's proposal...
Clavis Pharma raises NOK 154 million (EUR 19 million) in a private placement
Clavis Pharma ASA (OSE: CLAVIS) (the "Company") today announces that the Company has raised NOK 154 million ..
Notice of Extraordinary General Meeting
Clavis Pharma and Clovis Oncology Extend Partnership and Sign New $205 Million Deal for the Development and Commercialisation of Anti-Cancer Agent CP-4126 in Asia and Rest of the World
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug discovery and development company, and Clovis Oncology, Inc., announced today a new agreement ...
Invitation Meeting & Conference Call for Clavis Pharma's new $205 million deal with Clovis Oncology for the development & commercialisation of anti-cancer agent CP-4126 in Asia and Rest of the World
Clavis Pharma - Third Quarter Report 2010